| Year |
Citation |
Score |
| 2018 |
Pranzatelli MR, Tate ED, McGee NR, MacArthur CA. Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome. Pediatric Neurology. PMID 30197220 DOI: 10.1016/J.Pediatrneurol.2018.05.003 |
0.385 |
|
| 2018 |
Pranzatelli MR, Tate ED, McGee NR. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology ("Tumor" vs. "No tumor") in a cohort of 356 US children. Pediatric Blood & Cancer. e27097. PMID 29727049 DOI: 10.1002/Pbc.27097 |
0.306 |
|
| 2018 |
Pranzatelli MR, McGee NR, Tate ED. Relation of intrathecal oligoclonal band production to inflammatory mediator and immunotherapy response in 208 children with OMS. Journal of Neuroimmunology. PMID 29685330 DOI: 10.1016/J.Jneuroim.2018.04.007 |
0.373 |
|
| 2018 |
Pranzatelli MR, Allison TJ, Tate ED. Effect of low-dose cyclophosphamide, ACTH, and IVIG combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective pilot study. European Journal of Paediatric Neurology : Ejpn : Official Journal of the European Paediatric Neurology Society. PMID 29555260 DOI: 10.1016/J.Ejpn.2018.02.009 |
0.377 |
|
| 2018 |
Pranzatelli MR, Allison TJ, McGee NR, Tate ED. Cerebrospinal fluid γδ T cell frequency is age-related: a case control study of 435 children with inflammatory and non-inflammatory neurologic disorders. Clinical and Experimental Immunology. PMID 29485697 DOI: 10.1111/Cei.13122 |
0.412 |
|
| 2018 |
Pranzatelli MR, McGee NR. Neuroimmunology of OMS and ANNA-1/anti-Hu paraneoplastic syndromes in a child with neuroblastoma. Neurology(R) Neuroimmunology & Neuroinflammation. 5: e433. PMID 29318181 DOI: 10.1212/Nxi.0000000000000433 |
0.411 |
|
| 2018 |
Pranzatelli MR, Tate ED. Corrigendum to "Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome" [Pediatric Neurology 73 (2017) 48-56]. Pediatric Neurology. 78: 84. PMID 29169865 DOI: 10.1016/J.Pediatrneurol.2017.10.002 |
0.369 |
|
| 2017 |
Pranzatelli MR, Tate ED, Alber M, Awadalla M, Blumkin L, Lina ES, Leiz S, Móser J. Rituximab, IVIg, and Tetracosactide (ACTH1-24) Combination Immunotherapy ("RITE-CI") for Pediatric Opsoclonus-Myoclonus Syndrome: Immunomarkers and Clinical Observations. Neuropediatrics. PMID 29258131 DOI: 10.1055/S-0037-1609038 |
0.406 |
|
| 2017 |
Bielekova B, Pranzatelli MR. Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping. Seminars in Pediatric Neurology. 24: 229-239. PMID 29103430 DOI: 10.1016/J.Spen.2017.08.001 |
0.333 |
|
| 2017 |
Pranzatelli MR, Tate ED, McGee NR. Microglial/macrophage markers CHI3L1, sCD14, and sCD163 in CSF and serum of pediatric inflammatory and non-inflammatory neurological disorders: A case-control study and reference ranges. Journal of the Neurological Sciences. 381: 285-290. PMID 28991699 DOI: 10.1016/J.Jns.2017.09.006 |
0.355 |
|
| 2017 |
Pranzatelli MR, Tate ED, McGee NR. Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study. Frontiers in Neurology. 8: 468. PMID 28959231 DOI: 10.3389/Fneur.2017.00468 |
0.386 |
|
| 2017 |
Pranzatelli MR, Tate ED, Allison TJ. 6-Mercaptopurine Modifies Cerebrospinal Fluid T-cell Abnormalities in Pediatric Opsoclonus-Myoclonus as Steroid Sparer. Clinical and Experimental Immunology. PMID 28710878 DOI: 10.1111/Cei.13015 |
0.415 |
|
| 2017 |
Pranzatelli MR, Tate ED. Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome. Pediatric Neurology. PMID 28651977 DOI: 10.1016/J.Pediatrneurol.2017.04.027 |
0.353 |
|
| 2017 |
Pranzatelli MR, Tate ED, Allison TJ. Case-control, exploratory study of cerebrospinal fluid chemokines/cytokines and lymphocyte subsets in childhood Tourette syndrome with positive streptococcal markers. Cytokine. 96: 49-53. PMID 28288328 DOI: 10.1016/J.Cyto.2017.03.003 |
0.425 |
|
| 2016 |
Pranzatelli MR, Tate ED. Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome. Brain & Development. 38: 439-48. PMID 26786246 DOI: 10.1016/J.Braindev.2015.11.007 |
0.372 |
|
| 2014 |
Philipps G, Alisanski SB, Pranzatelli M, Clardy SL, Lennon VA, McKeon A. Purkinje cell cytoplasmic antibody type 1 (anti-Yo) autoimmunity in a child with Down syndrome. Jama Neurology. 71: 347-9. PMID 24424854 DOI: 10.1001/Jamaneurol.2013.4551 |
0.393 |
|
| 2014 |
Pranzatelli MR, Tate ED, McGee NR, Verhulst SJ. CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders. Journal of Neuroimmunology. 266: 75-81. PMID 24342231 DOI: 10.1016/J.Jneuroim.2013.11.004 |
0.39 |
|
| 2013 |
Pranzatelli MR, Tate ED, McGee NR, Ransohoff RM. CCR7 signaling in pediatric opsoclonus-myoclonus: Upregulated serum CCL21 expression is steroid-responsive Cytokine. 64: 331-336. PMID 23764550 DOI: 10.1016/J.Cyto.2013.05.020 |
0.355 |
|
| 2013 |
Pranzatelli MR, Tate ED, McGee NR, Colliver JA. Pediatric reference ranges for proinflammatory and anti-inflammatory cytokines in cerebrospinal fluid and serum by multiplexed immunoassay Journal of Interferon and Cytokine Research. 33: 523-528. PMID 23659672 DOI: 10.1089/Jir.2012.0132 |
0.324 |
|
| 2013 |
Pranzatelli MR, Tate ED, Mcgee NR, Travelstead AL, Verhulst SJ, Ransohoff RM. Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome Clinical and Experimental Immunology. 172: 427-436. PMID 23600831 DOI: 10.1111/Cei.12065 |
0.416 |
|
| 2013 |
Tate ED, Pranzatelli MR. Response to Correspondence on "active Comparator-Controlled, Rater-Blinded Study of Corticotropin-Based Immunotherapies for Opsoclonus-Myoclonus Syndrome" Journal of Child Neurology. 28: 417-418. PMID 23400632 DOI: 10.1177/0883073812469054 |
0.318 |
|
| 2013 |
Pranzatelli MR, Tate ED, McGee NR, Colliver JA. Cytokines, cytokine antagonists, and soluble adhesion molecules in pediatric OMS and other neuroinflammatory disorders Journal of the Neurological Sciences. 326: 53-58. PMID 23380454 DOI: 10.1016/J.Jns.2013.01.011 |
0.374 |
|
| 2013 |
Pranzatelli MR, Tate ED, McGee NR, Colliver JA, Ransohoff RM. CCR4 agonists CCL22 and CCL17 are elevated in pediatric OMS sera: Rapid and selective down-regulation of CCL22 by ACTH or corticosteroids Journal of Clinical Immunology. 33: 817-825. PMID 23340773 DOI: 10.1007/S10875-013-9867-4 |
0.368 |
|
| 2013 |
Pranzatelli MR, Tate ED, McGee NR, Travelstead AL, Colliver JA, Ness JM, Ransohoff RM. BAFF/APRIL system in pediatric OMS: Relation to severity, neuroinflammation, and immunotherapy Journal of Neuroinflammation. 10. PMID 23324534 DOI: 10.1186/1742-2094-10-10 |
0.443 |
|
| 2013 |
Pranzatelli MR, Tate ED, McGee NR, Ransohoff RM. 200: Pharmacodynamics of immunotherapy for opsoclonus–myoclonus syndrome: Impact on cytokines/chemokines Cytokine. 63: 290. DOI: 10.1016/J.Cyto.2013.06.203 |
0.413 |
|
| 2012 |
Pranzatelli MR, Tate ED, McGee NR, Travelstead AL, Ransohoff RM, Ness JM, Colliver JA. Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS Journal of Neuroimmunology. 243: 81-88. PMID 22264765 DOI: 10.1016/J.Jneuroim.2011.12.014 |
0.387 |
|
| 2012 |
Pranzatelli MR, Tate ED, Shenoy S, Travelstead AL. Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus Pediatric Blood and Cancer. 58: 988-991. PMID 21618414 DOI: 10.1002/Pbc.23187 |
0.389 |
|
| 2011 |
Pranzatelli MR, Slev PR, Tate ED, Travelstead AL, Colliver JA, Joseph SA. Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus. Pediatric Neurology. 45: 27-33. PMID 21723456 DOI: 10.1016/J.Pediatrneurol.2011.02.012 |
0.345 |
|
| 2011 |
Pranzatelli MR, Tate ED, Travelstead AL, Verhulst SJ. Chemokine/cytokine profiling after rituximab: Reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS Cytokine. 53: 384-389. PMID 21211990 DOI: 10.1016/J.Cyto.2010.12.004 |
0.381 |
|
| 2010 |
Pranzatelli MR, Tate ED, Swan JA, Travelstead AL, Colliver JA, Verhulst SJ, Crosley CJ, Graf WD, Joseph SA, Kelfer HM, Raju GP. B cell depletion therapy for new-onset opsoclonus-myoclonus. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 238-42. PMID 20063398 DOI: 10.1002/Mds.22941 |
0.407 |
|
| 2010 |
Pranzatelli MR, Tate ED, Travelstead AL, Colliver JA. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus Journal of Clinical Immunology. 30: 106-113. PMID 19838774 DOI: 10.1007/S10875-009-9335-3 |
0.407 |
|
| 2009 |
Pranzatelli MR, Tate ED, Travelstead AL, Baumgardner CA, Gowda NV, Halthore SN, Kerstan P, Kossak BD, Mitchell WG, Taub JW. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil Journal of Child Neurology. 24: 316-322. PMID 19258290 DOI: 10.1177/0883073808324217 |
0.428 |
|
| 2008 |
Pranzatelli MR, Tate ED, Hoefgen ER, Swan JA, Colliver JA. Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome. Cytokine. 44: 26-32. PMID 18675552 DOI: 10.1016/J.Cyto.2008.06.001 |
0.44 |
|
| 2006 |
Pranzatelli MR, Tate ED, Travelstead AL, Barbosa J, Bergamini RA, Civitello L, Franz DN, Greffe BS, Hanson RD, Hurwitz CA, Kalinyak KA, Kelfer H, Khakoo Y, Mantovani JF, Nicholson SH, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. Journal of Pediatric Hematology/Oncology. 28: 585-93. PMID 17006265 DOI: 10.1097/01.Mph.0000212991.64435.F0 |
0.423 |
|
| 2005 |
Pranzatelli MR, Chun KY, Moxness M, Tate ED, Allison TJ. Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: effect of therapy. Pediatric Neurology. 33: 121-6. PMID 16087057 DOI: 10.1016/J.Pediatrneurol.2005.03.004 |
0.368 |
|
| 2005 |
Pranzatelli MR, Tate ED, Travelstead AL, Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome Pediatrics. 115. PMID 15601813 DOI: 10.1542/Peds.2004-0845 |
0.397 |
|
| 2004 |
Pranzatelli MR, Hyland K, Tate ED, Arnold LA, Allison TJ, Soori GS. Evidence of cellular immune activation in children with opsoclonus-myoclonus: cerebrospinal fluid neopterin. Journal of Child Neurology. 19: 919-24. PMID 15704863 DOI: 10.1177/08830738040190120201 |
0.407 |
|
| 2004 |
Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Lee ND, Fisher J, Jasty R. Immunophenotype of blood lymphocytes in neuroblastoma-associated opsoclonus-myoclonus. Journal of Pediatric Hematology/Oncology. 26: 718-23. PMID 15543005 DOI: 10.1097/00043426-200411000-00006 |
0.317 |
|
| 2004 |
Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 770-7. PMID 15254934 DOI: 10.1002/Mds.20125 |
0.434 |
|
| 2004 |
Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Moticka EJ, Franz DN, Nigro MA, Parke JT, Stumpf DA, Verhulst SJ. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology. 62: 1526-32. PMID 15136676 DOI: 10.1212/Wnl.62.9.1526 |
0.665 |
|
| 2004 |
Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Moticka EJ, Franz DN, Nigro MA, Parke JT, Stumpf DA, Verhulst SJ. B- and t-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes American Journal of Ophthalmology. 138: 319. DOI: 10.1016/J.Ajo.2004.06.052 |
0.649 |
|
| 2003 |
Pranzatelli MR. A forward look at therapy for pediatric movement disorders. Seminars in Pediatric Neurology. 10: 103-10. PMID 12785754 DOI: 10.1016/S1071-9091(02)00009-8 |
0.314 |
|
| 2003 |
Pranzatelli MR. Myoclonus in childhood. Seminars in Pediatric Neurology. 10: 41-51. PMID 12785747 DOI: 10.1016/S1071-9091(02)00008-6 |
0.317 |
|
| 2002 |
Pranzatelli MR, Tate ED, Wheeler A, Bass N, Gold AP, Griebel ML, Gumbinas M, Heydemann PT, Holt PJ, Jacob P, Kotagal S, Minarcik CJ, Schub HS. Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatric Neurology. 27: 384-7. PMID 12504207 DOI: 10.1016/S0887-8994(02)00457-5 |
0.337 |
|
| 2002 |
Pranzatelli MR, Tate ED, Kinsbourne M, Caviness VS, Mishra B. Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIG. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 1387-90. PMID 12465092 DOI: 10.1002/Mds.10283 |
0.316 |
|
| 2000 |
Pranzatelli MR. Paraneoplastic syndromes: an unsolved murder. Seminars in Pediatric Neurology. 7: 118-130. PMID 10914413 DOI: 10.1053/Pb.2000.6695 |
0.332 |
|
| 1998 |
Pranzatelli MR, Hanin I, Tate E, Kindel G, Bergin A, Brown CM, Habersang P, Habersang R, Mack KJ, Rosenbaum B, Selby KA, Vasconcellos M. Cerebrospinal fluid free choline in movement disorders of paediatric onset. European Journal of Paediatric Neurology : Ejpn : Official Journal of the European Paediatric Neurology Society. 2: 33-9. PMID 10726844 DOI: 10.1016/1090-3798(98)01003-3 |
0.373 |
|
| 1998 |
Pranzatelli MR, Huang YY, Tate E, Goldstein DS, Holmes CS, Goldstein EM, Ketner K, Kinast M, Lange BM, Sanz A, Shevell MI, Stanford RE, Taff IP. Monoaminergic effects of high-dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 522-8. PMID 9613746 DOI: 10.1002/Mds.870130323 |
0.374 |
|
| 1996 |
Pranzatelli MR. Oral pharmacotherapy for the movement disorders of cerebral palsy. Journal of Child Neurology. 11. PMID 8959457 DOI: 10.1177/0883073896011001S03 |
0.301 |
|
| 1996 |
Pranzatelli MR. The immunopharmacology of the opsoclonus-myoclonus syndrome. Clinical Neuropharmacology. 19: 1-47. PMID 8867515 DOI: 10.1097/00002826-199619010-00001 |
0.33 |
|
| 1996 |
Pranzatelli MR. Movement Disorders in Childhood Pediatrics in Review. 17: 388-394. DOI: 10.1542/Pir.17-11-388 |
0.325 |
|
| 1995 |
Mott SH, Packer RJ, Vezina LG, Kapur S, Dinndorf PA, Conry JA, Pranzatelli MR, Quinones RR. Encephalopathy with parkinsonian features in children following bone marrow transplantations and high-dose amphotericin B. Annals of Neurology. 37: 810-4. PMID 7778856 DOI: 10.1002/Ana.410370616 |
0.319 |
|
| 1995 |
Pranzatelli MR, Tate E, Huang Y, Haas RH, Bodensteiner J, Ashwal S, Franz D. Neuropharmacology of Progressive Myoclonus Epilepsy: Response to 5-Hydroxy-L-Tryptophan Epilepsia. 36: 783-791. PMID 7543407 DOI: 10.1111/J.1528-1157.1995.Tb01615.X |
0.308 |
|
| 1995 |
Pranzatelli MR, Huang Y, Tate E, Stanley M, Noetzel MJ, Gospe SM, Banasiak K. Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in the pediatric opsoclonus-myoclonus syndrome. Annals of Neurology. 37: 189-97. PMID 7531417 DOI: 10.1002/Ana.410370209 |
0.341 |
|
| 1995 |
Papero PH, Pranzatelli MR, Margolis LJ, Tate E, Wilson LA, Glass P. Neurobehavioral and psychosocial functioning of children with opsoclonus-myoclonus syndrome. Developmental Medicine and Child Neurology. 37: 915-32. PMID 7493725 DOI: 10.1111/J.1469-8749.1995.Tb11944.X |
0.323 |
|
| 1994 |
Pranzatelli MR, Mott SH, Pavlakis SG, Conry JA, Tate ED. Clinical spectrum of secondary Parkinsonism in childhood: A reversible disorder Pediatric Neurology. 10: 131-140. PMID 8024661 DOI: 10.1016/0887-8994(94)90045-0 |
0.381 |
|
| 1992 |
Baska RE, Pranzatelli MR. Hypothalamic-midbrain dysregulation syndrome. Journal of Child Neurology. 7: 116-117. PMID 1552145 DOI: 10.1177/088307389200700121 |
0.315 |
|
| 1992 |
Pranzatelli MR. The neurobiology of the opsoclonus-myoclonus syndrome. Clinical Neuropharmacology. 15: 186-228. PMID 1394242 DOI: 10.1097/00002826-199206000-00002 |
0.343 |
|
| Show low-probability matches. |